Merck Quarterly Income Statement
NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Merck revenue and earnings
In the quarter ended Jun 30, 2026, Merck generated $16.61 billion in revenue, up 5.1% from the same quarter a year earlier. Merck reported a net loss of $1.33 billion, compared with net income of $4.43 billion a year earlier. Gross margin was 73.5% (down from 77.5%).
Diluted earnings per share came in at -$0.54, down from $1.76.
Summary generated from market data by MetaCap's automated system. Methodology
Merck income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.61B | 16.29B | 16.40B | 17.28B | 15.81B | 15.53B | 15.62B | 16.66B | 16.11B | 15.78B | 14.63B | 15.96B |
| Revenue growth (YoY) | +5.07% | +4.87% | +4.97% | +3.72% | -1.90% | -1.56% | +6.79% | +4.35% | +7.16% | +8.89% | +5.78% | +6.70% |
| Cost of Revenue | 4.39B | 4.20B | 5.55B | 3.85B | 3.56B | 3.42B | 3.83B | 4.08B | 3.75B | 3.54B | 3.91B | 4.26B |
| Gross Profit | 12.21B | 12.09B | 10.85B | 13.42B | 12.25B | 12.11B | 11.80B | 12.58B | 12.37B | 12.23B | 10.72B | 11.70B |
| Research & Development | 9.74B | 12.59B | 3.89B | 4.23B | 4.05B | 3.62B | 4.58B | 5.86B | 3.50B | 3.99B | 9.63B | 3.31B |
| Selling, General & Admin | 2.90B | 2.70B | 2.90B | 2.63B | 2.65B | 2.55B | 2.86B | 2.73B | 2.74B | 2.48B | 2.80B | 2.52B |
| Interest Expense | 525.00M | 479.00M | 411.00M | 327.00M | 305.00M | 313.00M | 328.00M | 330.00M | 310.00M | 303.00M | 310.00M | 317.00M |
| Other Income (Expense) | -99.00M | -138.00M | -432.00M | 238.00M | 7.00M | 35.00M | -127.00M | 162.00M | -42.00M | 33.00M | -78.00M | -126.00M |
| Pretax Income | -683.00M | -3.53B | 3.42B | 6.75B | 5.00B | 5.90B | 4.17B | 4.09B | 6.01B | 5.67B | -2.05B | 5.62B |
| Income Tax | 654.00M | 709.00M | 458.00M | 958.00M | 571.00M | 818.00M | 426.00M | 929.00M | 545.00M | 903.00M | -820.00M | 870.00M |
| Net Income | -1.33B | -4.24B | 2.96B | 5.79B | 4.43B | 5.08B | 3.74B | 3.16B | 5.46B | 4.76B | -1.23B | 4.75B |
| Net Income growth (YoY) | -130.16% | -183.48% | -20.84% | +83.24% | -18.85% | +6.66% | — | -33.47% | — | +68.81% | -140.64% | +46.09% |
| EPS (Basic) | -0.54 | -1.72 | 1.21 | 2.32 | 1.76 | 2.01 | 1.48 | 1.25 | 2.15 | 1.88 | -0.49 | 1.87 |
| EPS (Diluted) | -0.54 | -1.72 | 1.19 | 2.32 | 1.76 | 2.01 | 1.49 | 1.24 | 2.14 | 1.87 | -0.48 | 1.86 |
| Shares Outstanding (Basic) | 2.47B | 2.47B | — | 2.50B | 2.51B | 2.52B | — | 2.53B | 2.53B | 2.53B | — | 2.54B |
| Shares Outstanding (Diluted) | 2.47B | 2.47B | — | 2.50B | 2.51B | 2.53B | — | 2.54B | 2.54B | 2.54B | — | 2.55B |
| Gross Margin | 73.54% | 74.24% | 66.15% | 77.69% | 77.50% | 77.98% | 75.50% | 75.51% | 76.76% | 77.56% | 73.26% | 73.29% |
| Net Margin | -8.04% | -26.03% | 18.07% | 33.49% | 28.01% | 32.71% | 23.96% | 18.95% | 33.86% | 30.19% | -8.38% | 29.73% |
This table shows 12 quarterly periods of Merck's income statement, from Q2 2026 back to Q3 2023, across 16 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MRK's reporting calendar. What is a income statement?